Implementation Strategies for Monitoring Adherence in Real Time (iSMART)
Primary Purpose
Lung Cancer, Medication Adherence, Symptoms and Signs
Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Conversational Agent/Chatbot
Usual Care
Sponsored by

About this trial
This is an interventional supportive care trial for Lung Cancer focused on measuring medication adherence, symptom management, non-small cell lung cancer, implementation science, digital health, behavioral science
Eligibility Criteria
Inclusion Criteria:
- Adult patient (age > 18 years) with NSCLC at UPHS who is receiving one of the following nine oral therapies: afatinib, erlotinib, dacomitinib, gefitinib, osimertinib, alectinib, brigatinib, crizotinib, or lorlatinib.
- Patient possession of a mobile device that can send/receive SMS texts
- Ability to respond to questions and engage with "Penny" in English
- Ability to provide informed consent to participate in the study
- Approval from the patient's medical oncologist to be approached
Exclusion Criteria:
- Inability to respond to questions and engage with "Penny" in English
- Inability or unwillingness to provide informed consent to participate in the study
- Inability to engage with SMS text-messaging platform
- Concurrent enrollment in a therapeutic clinical trial
- Taking more than one oral targeted therapy or concurrent chemotherapy during the study window
- Lack of approval from the patient's oncologist
Sites / Locations
- University of Pennsylvania
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Intervention Arm
Control Arm
Arm Description
Participants in the intervention arm will be tracked and able to engage with the intervention (conversational agent) on their mobile telephone for 12 weeks.
Patients in the control arm will receive usual care, which includes clinician-driven education on medication management and self-monitoring of symptoms.
Outcomes
Primary Outcome Measures
Adherence
Defined as the number of adherent days divided by number of prescribed days. Adherent days will be calculated dichotomously based on whether a patient took all prescribed doses for the day within 2 hours of recommended time. Adherence data will be assessed via MEMS caps, which capture a date and time stamp each time the pill bottle is opened.
Secondary Outcome Measures
Persistence
Defined as the number of consecutive days on the regimen and conversely gaps in overall treatment, measured using MEMS caps.
Full Information
NCT ID
NCT04347161
First Posted
April 1, 2020
Last Updated
January 30, 2023
Sponsor
Abramson Cancer Center at Penn Medicine
Collaborators
Lung Cancer Research Foundation, Pfizer
1. Study Identification
Unique Protocol Identification Number
NCT04347161
Brief Title
Implementation Strategies for Monitoring Adherence in Real Time
Acronym
iSMART
Official Title
Implementation Strategies for Monitoring Adherence in Real Time
Study Type
Interventional
2. Study Status
Record Verification Date
January 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
February 22, 2021 (Actual)
Primary Completion Date
August 31, 2022 (Actual)
Study Completion Date
November 29, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Abramson Cancer Center at Penn Medicine
Collaborators
Lung Cancer Research Foundation, Pfizer
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
No
5. Study Description
Brief Summary
The objective of this project is to identify effective strategies to help patients with lung cancer manage side effects and achieve optimal adherence to oral targeted therapies. To achieve this objective, we will evaluate the effect of a novel, bidirectional conversational agent, compared to usual care, on adherence to oral targeted therapies using a two-arm randomized controlled trial, and explore how multilevel factors impact the acceptability and effectiveness of this strategy by collecting qualitative and quantitative data from clinicians and patients.
Detailed Description
Drawing from insights in behavioral economics and implementation science, the goal of our project is to identify effective strategies for improving lung cancer outcomes by helping patients to better manage symptoms and adhere to oral therapies. Given the rapid increase in FDA-approved targeted therapies, the need for such strategies will continue to grow. Our central hypothesis is that conversational agent will improve adherence to oral therapies by targeting patient-level determinants of behavior change. The specific aims are to: 1) Test the effects of a patient-directed intervention (conversational agent) to improve adherence to oral targeted therapies in patients with non-small cell lung cancer.; and 2) Use mixed-methods approaches with clinicians and patients to explore multilevel factors shaping the acceptability, effectiveness, and future implementation of intervention into routine cancer care. Primary trial outcomes (adherence and persistence) will be measured using microelectronic monitoring system (MEMS) caps. Secondary outcomes will be assessed using longitudinal surveys and medical record data.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lung Cancer, Medication Adherence, Symptoms and Signs
Keywords
medication adherence, symptom management, non-small cell lung cancer, implementation science, digital health, behavioral science
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Patients with lung cancer receiving oral targeted therapies at recruitment sites will be randomized (1:1 stratified by drug class and prescription status) to receive intervention or usual care.
Masking
Outcomes Assessor
Masking Description
Due to the nature of the intervention, participants and their care providers (including investigators) will not be blinded. The primary analyst and outcomes assessor will be blinded. Blinding may be broken in an emergency.
Allocation
Randomized
Enrollment
75 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Intervention Arm
Arm Type
Experimental
Arm Description
Participants in the intervention arm will be tracked and able to engage with the intervention (conversational agent) on their mobile telephone for 12 weeks.
Arm Title
Control Arm
Arm Type
Active Comparator
Arm Description
Patients in the control arm will receive usual care, which includes clinician-driven education on medication management and self-monitoring of symptoms.
Intervention Type
Device
Intervention Name(s)
Conversational Agent/Chatbot
Intervention Description
Via text messages, the bidirectional, conversation agent provides specific dosing instructions and motivational reminders to promote oral targeted therapy adherence and symptom management. Patients can report symptoms at any time via text message and are also prompted to report symptoms and medication adherence at periodic intervals. Reported symptoms are monitored and managed algorithmically according severity. High-grade symptoms are triaged directly to the patients' cancer care team. Patients in the intervention arm will use MEMS caps to enable capture of the primary outcome and asked to complete longitudinal surveys.
Intervention Type
Other
Intervention Name(s)
Usual Care
Intervention Description
Patients in the control arm will receive usual care, which includes receiving information about dosing and self-administration of oral therapy, and anticipatory guidance for patients regarding management of side effects. Patients in the control arm will use MEMS caps to enable capture of the primary outcome and asked to complete longitudinal surveys.
Primary Outcome Measure Information:
Title
Adherence
Description
Defined as the number of adherent days divided by number of prescribed days. Adherent days will be calculated dichotomously based on whether a patient took all prescribed doses for the day within 2 hours of recommended time. Adherence data will be assessed via MEMS caps, which capture a date and time stamp each time the pill bottle is opened.
Time Frame
12 weeks after study initiation or at therapy discontinuation, whichever is shorter
Secondary Outcome Measure Information:
Title
Persistence
Description
Defined as the number of consecutive days on the regimen and conversely gaps in overall treatment, measured using MEMS caps.
Time Frame
12 weeks after study initiation or at therapy discontinuation, whichever is shorter
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adult patient (age > 18 years) with NSCLC at UPHS who is receiving one of the following nine oral therapies: afatinib, erlotinib, dacomitinib, gefitinib, osimertinib, alectinib, brigatinib, crizotinib, or lorlatinib.
Patient possession of a mobile device that can send/receive SMS texts
Ability to respond to questions and engage with "Penny" in English
Ability to provide informed consent to participate in the study
Approval from the patient's medical oncologist to be approached
Exclusion Criteria:
Inability to respond to questions and engage with "Penny" in English
Inability or unwillingness to provide informed consent to participate in the study
Inability to engage with SMS text-messaging platform
Concurrent enrollment in a therapeutic clinical trial
Taking more than one oral targeted therapy or concurrent chemotherapy during the study window
Lack of approval from the patient's oncologist
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Katharine A Rendle, PhD,MSW,MPH
Organizational Affiliation
University of Pennsylvania
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Samuel U Takvorian, MD, MSHP
Organizational Affiliation
University of Pennsylvania
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Pennsylvania
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Implementation Strategies for Monitoring Adherence in Real Time
We'll reach out to this number within 24 hrs